Strategic Partnerships Position Excision BioTherapeutics for collaboration with CROs and academic partners active in CRISPR and viral therapies, highlighting their preclinical HBV and HSV programs and ongoing clinical ambitions to attract joint development or sponsored research opportunities.

Clinical Pipeline Leverage their focus on CRISPR-based therapies for latent viral infections to explore advisory or co-development roles with biotech firms seeking gene-editing capabilities for HIV, HBV, and other persistent viral diseases.

Funding Readiness Emphasize near-term milestones achievable with current funding and a $138M backing to align potential investors or partners with upcoming preclinical data presentations and key symposiums to accelerate collaborations.

Diverse Revenue Signals Acknowledge multiple revenue prospects from research partnerships, sponsored studies, and potential licensing of CRISPR platform insights, given their small to mid-size company scale and ongoing preclinical achievements.

Market Visibility Capitalize on recognition such as Fierce 15 and attendance at major events like ICE-HBV and ASGCT to craft timely BD outreach, highlighting credibility and momentum to prospective collaborators and investors.